QP2 aims to deliver significant value through optimizing dosage, identifying opportunities to halt development of undifferentiated assets, and streamlining the development of promising compounds and biologics, all of which contribute to life-changing therapies for patients. Our core strength has been in the areas of dose selection and characterization of pharmacokinetic (PK) and pharmacodynamic (PD) properties, while we continue to grow our strategy in areas such as informing the feasibility of targets in discovery, growing the impact of modeling in vaccine development and investing in advanced data science capabilities to enable the use of digital and real-world data.